Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pociredir in Sickle Cell Disease
NCT05169580Phase 1Completed
- Sponsor
- Fulcrum Therapeutics
- Start
- Dec 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of pociredir in sickle cell disease (SCD), sponsored by Fulcrum Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 16 weeks and Plasma Concentrations of Pociredir at 91 days. Started Dec 2021; status: completed.
02
Drugs
pociredir
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05169580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169580.